Case reports: Could sexual dysfunction in women with migraine be a side effect of CGRP inhibition?

Linda Al-Hassany, Deirdre M Boucherie, Emile G M Couturier, Antoinette MaassenVanDenBrink*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review



The development and approval of antibodies targeting calcitonin gene-related peptide or its receptor mark a revolutionary era for preventive migraine treatment. Real-world evidence sheds light on rare, stigmatized or overlooked side effects of these drugs. One of these potential side effects is sexual dysfunction.


We present two cases of one 42-year-old and one 45-year-old female patient with chronic migraine who both reported sexual dysfunction as a possible side effect of treatment with galcanezumab, a monoclonal antibody targeting calcitonin gene-related peptide.


As calcitonin gene-related peptide is involved in vaginal lubrication as well as genital sensation and swelling, inhibiting the calcitonin gene-related peptide pathway may lead to sexual dysfunction as a potential side effect.


Sexual dysfunction in female migraine patients might be a rare and overlooked side effect of monoclonal antibodies targeting the calcitonin gene-related peptide pathway. Considering the discomfort and stigma surrounding both migraine and sexual dysfunction, we advocate for an open attitude and awareness among clinicians toward such side effects.

Original languageEnglish
Article number3331024241248837
JournalCephalalgia : an international journal of headache
Issue number5
Publication statusPublished - 26 May 2024

Bibliographical note

Publisher Copyright:
© International Headache Society 2024.


Dive into the research topics of 'Case reports: Could sexual dysfunction in women with migraine be a side effect of CGRP inhibition?'. Together they form a unique fingerprint.

Cite this